Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial - Rugo, Hope S.; Bardia, Aditya; Marmé, Frederik; Cortés, Javier; Schmid, Peter; Loirat, Delphine; Trédan, Olivier; Ciruelos, Eva; Dalenc, Florence; Gómez Pardo, Patricia; Jhaveri, Komal L; Delaney, Rosemary; et al. (The lancet, 2023)
Online veröffentlicht: 23. August 2023, Artikelversion: 19. Oktober 2023